American Regent, Inc.

Clinical trials sponsored by American Regent, Inc., explained in plain language.

Now part of Daiichi Sankyo Company, Limited DSNKY OTC

Pharmaceutical company manufacturing injectable drugs.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Completed 2 Terminated 1

Experimental liver cancer drug shows promise in early trial

Disease control Stopped early

This phase 2 trial tested a drug called Taxoprexin (DHA-paclitaxel) in 13 people with advanced liver cancer that had not responded to prior treatments. The goal was to see if the drug could shrink tumors and how safe it was. The study was terminated early, so results are limited.

Phase 2 • Sponsor: American Regent, Inc. • Aim: Disease control

Last updated Jun 27, 2026 07:54 UTC

American Regent, Inc.

Experimental liver cancer drug shows promise in early trial